Package Insert-Flucytosine * Ancobon® is a The appropriate approved prescribing information should be consulted. Images. Group: antifungal. Capsule, mg [EDL] Solution for injection, g in ml [ EDL]. General information. Flucytosine is a fluorinated pyrimidine, non-antibiotic . Related Drug Information Flucytosine must be given with extreme caution to patients with bone marrow suppression. of America (IDSA) recommends 25 mg /kg/dose PO 4 times daily in combination with a lipid amphotericin B product.
|Published (Last):||24 July 2012|
|PDF File Size:||2.77 Mb|
|ePub File Size:||4.89 Mb|
|Price:||Free* [*Free Regsitration Required]|
Flucytosine is a fluorinated pyrimidine, non-antibiotic antifungal agent. Flucytosine is deaminated to fluorouracil in fungal cells. It is believed to act as an antimetabolite by competing with uracil, thereby interfering with pyrimidine metabolism and ultimately RNA and protein synthesis.
Informatioj is readily absorbed from the gut and is widely distributed through out body tissues and fluids including the CSF. It is excreted mainly unchanged via the kidneys.
The plasma half-life is 2. Flucytosine may effect rapidly proliferating tissues, particularly the bone marrow and lining of the GI tract. The risk of bone marrow suppression appears to be increased if high serum concentration of flucytosine occur.
Flucytosine should only inrormation used during pregnancy when the potential benefits justify the possible risks to the foetus. Moderate hypoplasia of the bone marrow resulting in anaemia, leukopenia, pancytopenia, thrombocytopenia, or rarely agranulocytosis may occur.
Death from aplastic anaemia has been reported. Nausea, vomiting, anorexia, prescribiing bloating, diarrhoea, and rarely bowel perforation, and rash have also been reported.
Confusion, hallucinations, headaches, sedation, vertigo, and liver enlargement have been reported more rarely. Possible additive toxicity with other myelosuppressive drugs e. The dose of flucytosine needs to inforation in renal failure. Therefore caution with nephrotoxic drugs e.
Ancotil g/ml Solution for Infusion – Summary of Product Characteristics (SmPC) – (eMC)
In the event of flucytosine overdosage the manufacturer recommends prompt use of gastric lavage or an emetic. Because flucytosine is eliminated essentially unchanged in urine, adequate fluid intake should be maintained and IV fluids given if necessary.
Haematological parameters should be assessed frequently and liver and kidney function carefully monitored. Consideration should be given to the use of haemodialysis, which readily removes the drug in anuric patients. The solution for injection should not be allowed to freeze as precipitation will occur.
Contraindications Known hypersensitivity anaphylaxis has been reported Pre-existing bone marrow depression Precautions Flucytosine may effect rapidly proliferating tissues, particularly the bone marrow and lining of the GI tract.
Reduce the dose in patients prescriving renal impairment Use in pregnancy Flucytosine should only be used during pregnancy when the potential benefits justify the possible inofrmation to the foetus.
Ancotil 2.5g/250ml Solution for Infusion
Adverse effects Moderate hypoplasia of the bone marrow resulting in anaemia, leukopenia, pancytopenia, thrombocytopenia, or rarely agranulocytosis may occur. Drug interactions Possible additive toxicity with other myelosuppressive drugs e. Overdosage In the event of flucytosine overdosage the manufacturer recommends prompt use of gastric lavage or an emetic. Site prescribinb disease – Potential opportunistic of disease.
Pneumonia due to Pneumocystis carinii PCP.
Mycobacterium avium complex MAC. Mucocutaneous and cutaneous eruptions. Oral and oesophageal candidiasis.